Expand The

Horizon

Each allogeneic hematopoietic stem cell transplant (allo-HSCT) is a personalized journey.

No paths are exactly alike,

but the outlook is the same:

hope on the horizon.

Join us on a new journey to extend the promise of allo-HSCT to more patients in need.

As cell therapy innovations redefine expectations of allo-hsct,
what new perspectives will lead us to:

Open the field

with more transplants for more waiting patients?

smooth the path

with optimized solutions and better outcomes?

clear the way

with a straightforward experience for patients?

Continue to find out more about today's landscape.

THE LANDSCAPE TODAY
THE LANDSCAPE TODAY

Over 18,000 new patients with hematologic malignancies are considered for allogeneic transplant each year, initiating their journey of hope.1

ALLO-HSCT OFFERS A CRITICAL ADVANTAGE to these patients by significantly improving survival rates when they proceed to transplant earlier in their treatment journey.2,3

ADVANCES IN THE LAST FEW DECADES HAVE SIGNIFICANTLY IMPROVED
ALLO-HSCT ACCESS AND OUTCOMES. SELECT TO FIND OUT MORE:

1970
Advent of unrelated
donor registries
1980
Introduction
of umbilical cord blood
(UCB) as a viable graft source
1990
Process of peripheral blood stem cell collection
Emergence
of reduced intensity conditioning regimens
2000
Increased sensitivity of chimerism analysis methods
2010
Improvement of post-transplant treatments for haploidentical recipients
2020
Development
of novel pharmaceutical agents as new treatment options
First established in 1974, this introduced a monumental shift that extended access to new donor sources for patients without access to a matched related donor.2

CONTINUE TO LEARN ABOUT CHALLENGES ALONG THE TRANSPLANT JOURNEY.

ADVANCES IN THE LAST FEW DECADES HAVE SIGNIFICANTLY IMPROVED
ALLO-HSCT ACCESS AND OUTCOMES. SELECT TO FIND OUT MORE:

1970

Advent of unrelated
donor registries

1980

Introduction
of umbilical cord blood
(UCB) as a viable graft source

1990

Process of peripheral blood stem cell collection
Emergence
of reduced intensity conditioning regimens

2000

Increased sensitivity of chimerism analysis methods

2010

Improvement of post-transplant treatments for haploidentical recipients

2020

Development
of novel pharmaceutical agents as new treatment options
First established in 1974, this introduced a monumental shift that extended access to new donor sources for patients without access to a matched related donor.2

CONTINUE TO LEARN ABOUT CHALLENGES ALONG THE TRANSPLANT JOURNEY.

A CHALLENGING JOURNEY
A CHALLENGING JOURNEY

Allogeneic transplant is a POTENTIALLY CURATIVE TREATMENT for patients with hematologic malignancies, but despite our achievements as a community, the transplant journey remains challenging.2

Every year, MORE THAN 10,000 PATIENTS who could benefit from allo-HSCT do not receive a transplant, and those who do experience anxiety and face challenges across the entire transplant journey.10,11

Racial disparities contribute to the lack of access to allo-transplant, and MINORITY PATIENTS ARE FAR LESS LIKELY to find a suitable donor.12,13,14

Navigate the patient journey to learn more about steps
and barriers along the way.

Patient Selection and Consideration for Transplant

Once referred to a transplanter, the determination of allo-HSCT eligibility and decision to proceed is complex, and reliant on clinical, non-clinical, and donor factors.11

Learn More About Clinical Barriers

Learn more about Non-Clinical Barriers

Donor sourcing and acquisition

The search for a donor source requires the full transplant team and may be unpredictable due to donor accessibility and the possibility of donor attrition. Selection of a donor source is ultimately at the discretion of the transplanter, and acquisition can range from 1 to 14+ months.15,16

Learn more about Donor-Related Barriers

Patient Preparation

Patients undergo myeloablative or reduced intensity conditioning before their infusion. In preparation for transplantation, and for the subsequent recovery period after undergoing allo-HSCT, patients need to secure a full-time caregiver and a strong support system.2,11

Transplantation

Day Zero represents the day of infusion of stem cells and also the beginning of the monitoring period, which requires careful planning and preparation by the transplant team, the patient, and their caregiver.2

Recovery, Monitoring, and Long-term Follow-up

The time from transplant to engraftment is a key indicator of transplant success, and the days following transplant are critical for monitoring of patient outcomes. This period of monitoring continues even after engraftment and discharge, with transplanters consistently following up to mitigate complications and track progress.2,17

BARRIERS THROUGHOUT THE JOURNEY PREVENT PATIENTS FROM EVEN BEING CONSIDERED FOR AND PROCEEDING WITH TRANSPLANT, EXCLUDING THEM FROM THIS POTENTIAL CURE.

CONTINUE TO LEARN MORE ABOUT RACIAL DISPARITIES TO ACCESS.

HSCT DISPARITY
HSCT DISPARITY

For minority patients, additional barriers exist throughout the journey, with ACCESS TO A DONOR VARYING GREATLY BY RACE.

In the U.S., African Americans are 2–3 times less likely than White Americans to find a matched unrelated donor, and disproportionately receive a mismatched graft: 41% of the time, as compared to 14% for White Americans.38-40

Probability of identifying an 8/8 HLA-matched
unrelated available adult donor by race13

White patients of European descent

75%

White patients of Middle Eastern or North African descent

46%

Hispanic patients (includes Mexican, Hispanic South
or Central American, and Hispanic Caribbean)

34%–40%

Asian patients (includes Chinese, Korean, South Asian,
Japanese, Filipino, Southeast Asian, and Vietnamese)

27%–42%

Black patients (includes African American, African,
Black South or Central American, and Black Caribbean)

16%–19%

Data obtained from the National Marrow Donor Program registry was used to predict the likelihood of identifying a suitable donor for patients in each group.

SOLUTIONS TODAY OFTEN FOCUS ON ALTERNATIVE DONOR SOURCES,
BUT STILL, INEQUITIES REMAIN.41,42

Cord Blood increases minority patients’ access to a suitable graft with less strict HLA matching as compared to adult donors.43,44 However, a single unit of cord blood may not supply enough hematopoietic cells for engraftment often requiring a second cord blood unit, preventing widespread adoption of cord blood transplantation.13

Haplo-related Transplant promises an almost universal match for many patients, but practical and clinical limitations pose considerable risks.45 Most patients of African ancestry do not have a suitable haplo-related donor; in a single-center study, only 44% of African Americans were able to identify a suitable HLA-haplo-related relative.42,46 Haplo-related transplants also often lead to high incidences of graft rejection and graft versus host disease (GvHD).45

Continue to learn about advancements in the allo-HSCT landscape.

SEEKING CHANGE
SEEKING CHANGE

Determination of transplant success is complex, and requires EVALUATION OF MULTIPLE PERFORMANCE INDICATORS across a period of time.

Transplant physicians and healthcare providers must manage outcomes while also seeking opportunities to increase equity in transplant.

But today, as NEW VISTAS IN CELL ENGINEERING AND TECHNOLOGY EMERGE, innovations will lead us to the next step in expectations for donor sources and transplant outcomes.

WHERE ARE NEW PROMISING ADVANCEMENTS HAPPENING
IN THE ALLO-HSCT LANDSCAPE?

EX VIVO
EXPANSION

NOVEL
HLA TYPING

OPTIMIZATION
OF CONDITIONING REGIMENS

SELECTION OF
OPTIMAL DONOR SOURCE

GvHD
PROPHYLAXIS
AND TREATMENT

GRAFT ENGINEERING
AND ADOPTIVE IMMUNOTHERAPY

SUPPORTIVE
CARE

HEALTH EQUITY
AND ACCESS AMONG MINORITIES

Ex vivo expansion of stem cells may help to alleviate the issue of cell shortage for transplantation purposes. Development of optimal conditions for expansion and preservation of cellular functionality and phenotype during expansion may lead to critical advancements in cellular therapy.56

CONTINUE TO SEE HOW YOU CAN JOIN THE JOURNEY.

WHERE ARE NEW PROMISING ADVANCEMENTS HAPPENING
IN THE ALLO-HSCT LANDSCAPE?

EX VIVO
EXPANSION

NOVEL
HLA TYPING

OPTIMIZATION
OF CONDITIONING REGIMENS

SELECTION OF
OPTIMAL DONOR SOURCE

GvHD
PROPHYLAXIS
AND TREATMENT

GRAFT ENGINEERING
AND ADOPTIVE IMMUNOTHERAPY

SUPPORTIVE
CARE

HEALTH EQUITY
AND ACCESS AMONG MINORITIES

Ex vivo expansion of stem cells may help to alleviate the issue of cell shortage for transplantation purposes. Development of optimal conditions for expansion and preservation of cellular functionality and phenotype during expansion may lead to critical advancements in cellular therapy.56

CONTINUE TO SEE HOW YOU CAN JOIN THE JOURNEY.